CD14 and neoplasm: First, a global comparison of CADO48A+ and CD14+ CD5−CD21−MHCII−CD11b+ myeloid cell frequencies (relative to total PBMCs) in the peripheral blood of tumor-bearing versus control dogs revealed an increased frequency of the CADO48A+ myeloid population (putative PMN-MDSCs; 2.53% [0.93, 4.94]) in comparison to healthy dogs (0.78% [0.13, 1.95]; p = 1.8 × 10−12) and those with non-neoplastic inflammatory diseases (1.33% [0.31, 2.75]; p = 0.0024) (Supplementary Fig. S1B).